CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin
China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294) has announced that it has received...
SHE: 300294
CR Boya Bio-Pharmaceutical’s Strategic Foray: Acquiring Green Cross HK for $250M to Expand Biopharma Dominance
In a significant development for the biopharmaceutical industry, China Resources Medical Holdings Company Limited and...